Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...
Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...
Gilead Sciences, Inc. has received conditional marketing authorization from the European Commission (EC) for Seladelpar for the treatment of primary biliary cholangitis (PBC) ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary ...
Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...
(RTTNews) - Gilead Sciences Inc. (GILD) announced that the European Commission has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis in ...
Gilead Sciences’ seladelpar has won conditional marketing authorization to treat primary biliary cholangitis (PBC) alongside ...
GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive. We believe there ...
The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results